期刊文献+

不同剂量氟伐他汀对老年不稳定型心绞痛患者血清MMP-3水平的影响 被引量:5

下载PDF
导出
摘要 炎症细胞介导的斑块破裂是发生不稳定型心绞痛(UAP)的重要机制〔1〕。大量实验研究表明,斑块破裂直接诱因是大量炎细胞的浸润〔2〕。最近研究表明他汀类药物除了有降脂作用外还有抗炎作用,在稳定斑块、降低冠状动脉事件发生中其抗炎作用起到至关重要的作用〔3〕。大量的证据表明了他汀类药物在UAP早期治疗的重要临床价值,在冠心病的二级预防中,长期应用他汀类药物能显著改善冠心病患者的预后〔4〕,可显著降低冠心病患者的临床症状和病死率。本文探讨不同剂量氟伐他汀治疗老年UAP对基质金属蛋白酶(MMP)-3水平的影响。
作者 董丽宏
出处 《中国老年学杂志》 CAS CSCD 北大核心 2011年第16期3156-3157,共2页 Chinese Journal of Gerontology
  • 相关文献

参考文献6

  • 1Weissberg PL. Atherogenesis:current understanding of the causes of atheroma [ J]. Heart,2000 ;83 (2) :247-52.
  • 2张平,李颖莉,秦勤.他汀类药物在急性冠脉综合征中的应用及其进展[J].中国分子心脏病学杂志,2007,7(3):170-176. 被引量:16
  • 3Cfisby M, Nordln-Fredriksson G,Shah PK,et al. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques:implications for plaque stablization [ J]. Circulation ,2001 ; 103 (7) :926-33.
  • 4The long-term intervention with pravastatin in isehemic disease ( LIPID ) study group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broadrang of initial cholesterol levels[ J]. N Engl J Med, 1998 ;339 (19) :349-57.
  • 5不稳定性心绞痛诊断和治疗建议[J].中华心血管病杂志,2000,28(6):409-412. 被引量:2695
  • 6Shah PK. Pathophysiology of plaque rupture and the concept of plaque stablilization [ J ]. Cardiol Clin, 1996 ;14 ( 1 ) : 17-29.

二级参考文献47

  • 1[30]Tamai O,Matsnoka H,Itachc H,et al.Single LDL apharesis improves endothelium-dependent vasodilation in hypercholesterolemic humans[J].Circulation,1997,95 ;76-82.
  • 2[31]O' Driscoll G,Green D,Taylor RR,et al.Simvastatin,an HMG-Coenzyme A reductase inhibitor improve endothelial function within 1 month[J].Circulation,1997,95 ; 112621131.
  • 3[32]Kaesemeyer WH,Caldwell RB,Huang J Z,et al.Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions[J].J Am Coll Cardiol,1999; 33 ;234-241.
  • 4[33]Laufs U,Fata VL,Plutzky J,et al.Upregulation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors[J].Circulation,1998,97; 1129-1135.
  • 5[34]Walter DD,Rittig K,Bahlmann FH.Statin therapy accelerates reendothelialization;a novel effect involving mobilization and incorporation of bone marrowderived endothelial progenitor cells[J].Circulation,2002,105 ;3017-3024.
  • 6[35]Chirkov YY,Holmes AS,Willoughby SR,et al.Stable angina and acute coronary syndromes are associate with nitric oxide resistance in platelets[J].J Am Coll Cardiol,2001,37 ;1851-1857.
  • 7[36]Laufs U,Gertz K,Huang P,et al.Atorvastatin upregulates type Ⅲ nitric oxide synthase in thrombocytes,decreases platelet activation,and protects from cerebral ischemia in normocholesterolemic mice[J].Stroke,2000,31 ;2442-2449.
  • 8[37]Colli S,Eligine S,Lalli M,et al.Vastatins inhibit tissue factor in cultured human macrophages[J].Arterioscler Thromb Vasc Biol,1997,17 ;265-272.
  • 9[38]Baetta R,Camera M,Comparato C,et al.Fluvastatin reduces tissue factor expression and macrophage accumulation in carotid lesions of cholesterol-fed rabbits in the absence of lipid lowering[J].Arterioscler Thromb Vasc Biol,2002,22 ;692-698.
  • 10[39]Dangas G,Badimon JJ,Smith DA,et al.Pravastatin therapy in byperlipidemia;effects on thrombus formation and the systemic hemostatic profile[J].J Am Coll Cardiol,1999,33 ;1294-1304.

共引文献2709

同被引文献42

  • 1赵水平.他汀类抗动脉粥样硬化的非降脂作用[J].中华老年多器官疾病杂志,2005,4(2):90-92. 被引量:12
  • 2中国成人血脂异常防治指南[J].中华心血管病杂志,2007,35(5):390-419. 被引量:5223
  • 3郭艺芳,胡大一.老年患者的他汀类药物降胆固醇治疗[J].中华内科杂志,2007,46(11):893-894. 被引量:5
  • 40pstad TB,Pettersen A,Arnesen H,et al. The co-exis- tence of the IL-18 +183 A/G and MMP-9 -1562 C/T poly- morphisms is associated with clinical events in coronary artery disease patients[J]. PLoS One, 2013,8 (9) : e74498.
  • 5Springall R, Amezcua-Guerra LM, Gonzalez-Pacheco H, et al. Interferon-gamma increases the ratio of matrix met- alloproteinase-9/tissue inhibitor of metalloproteinase-1 in peripheral monocytes from patients with coronary arterydisease[J]. PLoS One, 2013,8 (8) : e72291.
  • 6Hsu TW,Kuo KL,Hung SC,et al. Progression of kidney- disease in non-diabetic patients with coronary artery dis- ease: predictive role of circulating matrix metallopro- teinase-2, -3, and -9[J]. PLoS One,2013,8(7) :e70132.
  • 7Xu X,Wang L,Xu C,et al. Variations in matrix metallo- proteinase-1,-3, and -9 genes and the risk of acute coro- nary syndrome and coronary artery disease in the Chinese Han population[J]. Coron Artery Dis, 2013,24 (4) : 259-265.
  • 8Golovkin AS,Matveeva VG,Grigor'ev EV,et al. Postop- erative dynamic changes in matrix metalloproteinase lev- els in patients with coronary artery bypass graft proce- dure complications[J]. Kardiologiia,2012,52(9):4-7.
  • 9Hou ZH, Lu B, Gao Y, et al. Matrix metalloproteinase-9 (MMP-9) and myeloperoxidase(MPO) levels in patients with nonobstructive coronary artery disease detected by coronary computed tomographic angiography[J]. Acad Ra- diol, 2013,20 ( 1 ) : 25 -31.
  • 10顾复生.对大型他汀类药物临床研究强化降脂治疗的分析[J].中华老年医学杂志,2008,27(8):636-638. 被引量:2

引证文献5

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部